Digestery
Longevity supplements › Rapamycin and Aging › Studies

Pooled review (meta-analysis)

In mice, pooled review of 23 infection studies: rapamycin raised survival after infection

Phillips and colleagues · GeroScience · 2023

Original title: Rapamycin not dietary restriction improves resilience against pathogens: a meta-analysis.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

In 23 mouse studies, rapamycin raised survival after infection (lnHR = - 0.72; CI = - 1.17, -0.28; p = 0.0015). Dietary restriction lowered it (lnHR = 0.80; CI = 0.08, 1.52; p = 0.03).

The study at a glance

Type of study
Pooled review (meta-analysis)
Who or what was studied
23 studies · Mice in 23 studies of infection
What was tested
Rapamycin or dietary restriction, compared with untreated mice, then infected with germs
What it measured
The question itself: aging and age-related decline
Who has a stake
No stake declared
No competing interests declared.
Journal
GeroScience, 2023
Source
PubMed record 36399256. This page is based on the abstract only.

How much this study counts

  • ✓Pools the results of 23 studies.
  • •A pooled review is only as strong as the studies it pools.
  • ✓Measured the question itself: aging and age-related decline.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a pooled review (meta-analysis), and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer
  • Part of the finding “Rapamycin lengthens life in mice and other animals”.
  • Summed up in “What reviews found”: Pooled 23 mouse studies (n = 1223) of survival after infection. Rapamycin raised survival while eating less lowered it. The authors call for human trials of rapamycin to boost immunity.
  • Open item for a person: Phillips 2023 kept relevant: mouse survival after infection, but mouse ages are not stated. Confirm it fits the aging outcome.

Other reviews on this question

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 2 fields after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.